Novel Digital Application for Patients With Acute Leukemia
This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.
| Condition(s) | Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy. |
| Who can participate | Inclusion Criteria: * Hospitalized patients (age \> 18 years) with a diagnosis of AML. * Initiating treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen or b) hypomethylating agents (HMA) +/- additional agents or modification of this regimen on a clinical trial. * Ability to comprehend and speak English as the digital apps are only available in English Note: Patients newly diagnosed as well as those with relapsed/refractory AML initiating treatment with intensive or HMA-based chemotherapy will be eligible to participate. Exclusion Criteria: * Patients with a diagnosis of acute promyelocytic leukemia * Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes |
| Ages | 18 Years to 120 Years |
| Sex | All |
| Lead sponsor | Massachusetts General Hospital |
| Locations | Boston, Massachusetts, United States; Durham, North Carolina, United States; Seattle, Washington, United States |
| Start date | 2024-10-21 |
| NCT ID | NCT06472128 |
| Official listing | https://clinicaltrials.gov/study/NCT06472128 |